US stock · Healthcare sector · Biotechnology
Company Logo

Idera Pharmaceuticals, Inc.

IDRANASDAQ

0.38

USD
-0.02
(-5.00%)
Market Closed
-0.92P/E
-1Forward P/E
-0.05P/E to S&P500
20.164MMarket CAP
- -Div Yield
Upcoming Earnings
7 Nov-11 Nov
Shares Short
8/31/22
761.88k
Short % of Float
1.85%
Short % of Shares Outs.
1.44%
% Held by Insiders
23.00%
% Held by Institutions
6.79%
Beta
1.39
PEG Ratio
- -
52w. high/low
1.11/0.30
Avg. Daily Volume
0.11M
Return %
Stock
S&P 500
1 year
(65.45)
(16.94)
3 years
(86.08)
24.30
5 years
(97.88)
48.01
Scale: |
High
Low
104.80
41.76
124.80
44.72
73.52
35.84
58.56
18.80
29.84
7.60
17.52
5.20
38.00
1.52
54.96
15.52
43.84
18.16
26.64
9.52
22.96
10.40
20.40
2.75
4.19
1.45
5.50
0.81
6.14
0.51
0.79
0.29
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
1.17
3.01
9.31
11.79
5.13
0.02
0.01
0.01
0.01
0.02
1.02
0.05
0.02
0.05
- -
- -
- -
Earnings per share
(7.95)
(4.98)
0.53
2.58
(5.72)
(6.89)
(5.57)
(3.32)
(3.73)
(3.38)
(2.41)
(3.35)
(2.25)
(1.98)
(3.33)
2.90
(0.42)
FCF per share
1.21
(6.56)
8.18
(5.37)
(6.25)
(5.56)
(5.76)
(3.12)
(3.13)
(3.04)
(1.79)
(2.82)
(1.95)
(1.56)
(1.00)
(0.73)
(0.38)
Dividends per share
- -
- -
- -
- -
- -
- -
0.17
0.19
0.08
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.04
0.62
0.14
0.04
0.03
0.01
- -
0.00
0.11
0.05
0.03
0.01
0.00
0.00
0.00
- -
- -
Book Value per sh.
5.89
2.91
7.83
11.31
10.53
3.48
1.92
5.91
4.19
5.81
6.48
5.47
2.41
(0.39)
(2.70)
0.87
0.60
Comm.Shares outs.
2
3
3
3
3
3
3
5
10
14
16
20
27
29
34
34
52
Avg. annual P/E ratio
(4.3)
(14.2)
174.0
19.9
(5.8)
(2.5)
(1.7)
(3.3)
(7.4)
(8.7)
(6.2)
(4.7)
(5.0)
(1.4)
(0.7)
0.7
(0.9)
P/E to S&P500
(0.2)
(0.8)
8.1
0.3
(0.3)
(0.2)
(0.1)
(0.2)
(0.4)
(0.4)
(0.3)
(0.2)
(0.2)
(0.1)
(0.0)
0.0
(0.0)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
1.8%
1.8%
0.3%
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
2
8
26
35
16
0
0
0
0
0
16
1
1
1
- -
- -
- -
Operating margin
(684.0)%
(184.5)%
1.9%
21.4%
(111.6)%
(48,783.0)%
(39,021.6)%
(38,657.4)%
(53,084.9)%
(19,616.9)%
(239.3)%
(7,368.8)%
(9,207.9)%
(3,181.4)%
(Infinity)%
(Infinity)%
(Infinity)%
Depreciation (m)
0
0
1
1
1
0
0
0
0
0
1
1
0
0
0
0
0
Net profit (m)
(17)
(13)
2
8
(18)
(24)
(19)
(18)
(39)
(49)
(38)
(66)
(60)
(57)
(113)
98
(22)
Income tax rate
(0.3)%
- -
(1.6)%
(0.6)%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net profit margin
(682.5)%
(165.5)%
5.7%
21.9%
(111.5)%
(44,860.4)%
(37,725.5)%
(38,778.7)%
(52,934.2)%
(19,500.0)%
(237.0)%
(7,315.3)%
(9,045.5)%
(3,903.0)%
(Infinity)%
Infinity%
(Infinity)%
Working capital (m)
31
16
32
23
32
19
6
26
35
56
102
107
64
(8)
34
29
26
Long-term debt (m)
5
1
- -
- -
- -
- -
- -
- -
1
1
0
- -
- -
- -
- -
1
0
Equity (m)
12
8
22
33
33
12
7
32
43
84
103
108
64
(11)
(91)
29
26
ROIC
(49.5)%
(70.2)%
4.6%
22.6%
(53.9)%
(121.9)%
(287.5)%
(56.2)%
(87.1)%
(56.7)%
(36.9)%
(60.9)%
(93.5)%
804.1%
(103.7)%
(92.2)%
(77.8)%
Return on capital
(39.6)%
(47.1)%
2.7%
15.8%
(48.7)%
(92.9)%
(177.8)%
(49.4)%
(75.1)%
(52.5)%
(33.8)%
(55.7)%
(82.0)%
(119.0)%
(86.5)%
(79.4)%
(68.0)%
Return on equity
(135.0)%
(171.1)%
6.8%
22.8%
(54.3)%
(197.7)%
(290.3)%
(56.2)%
(89.0)%
(58.1)%
(37.1)%
(61.3)%
(93.6)%
506.0%
123.6%
333.0%
(84.5)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
103.0%
105.8%
102.1%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
(42.9)%
(0.3)%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.6%
- -
Capital Structure
5 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 4
Total assets
$ 30
Long-term debt
$ 0
Cash and equiv.
$ 28
Goodwill
$ - -
Retained earnings
$ (740)
Common stock
53
Enterprise Value
$ (7)
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
43
38
33
Receivables
- -
- -
- -
Inventory
- -
- -
- -
Other
3
(3)
(6)
Current assets
46
41
34
Acc. Payable
0
0
1
Debt due
0
0
0
Other
54
7
4
Current liabilities
55
7
5
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
- -
- -
- -
Cash flow
(27.18)%
(17.99)%
10.82%
Earnings
(187.07)%
(25.65)%
8.97%
Dividends
- -
- -
- -
Book value
(132.30)%
106.51%
107.77%
Insider Trading
Type
Shares
Date
Soland Daniel B
Award
66,500
07/06/22
Lim Bryant David
Award
66,500
07/06/22
Kirby John J.
Award
66,500
07/06/22
Milano Vincent
Award
124,000
07/06/22
Dougherty Michael R
Award
50,086
07/01/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.26
(0.72)
(0.61)
(2.27)
(3.33)
2021
3.42
(0.22)
(0.18)
(0.12)
2.90
2022
(0.08)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Vincent Milano
Full-time employees:
13
City:
Exton
Address:
505 Eagleview Blvd Ste 212
IPO:
Jan 25, 1996
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.